
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron’s NCT07753148 study is formally titled “An Open-Label, Multi-Center Phase I Study to Investigate the Safety and
Healthcare LdrIncmUn
Healthcare LdrIncmUn (TSE:HHL) is a dynamic exchange-traded fund (ETF) that offers investors targeted exposure to the ever-evolving healthcare sector. As a sector-focused fund, HHL is specifically designed for those looking to capitalize on the growth and innovation within the global healthcare industry, a crucial component of the economy known for its resilience and potential for substantial returns. This ETF provides a unique blend of income and growth by investing in a diversified portfolio of healthcare leaders, ranging from pharmaceuticals and biotechnology to medical devices and healthcare providers. By focusing on a broad-based niche within the healthcare sector, HHL enables investors to tap into the diverse opportunities presented by cutting-edge technologies, groundbreaking research, and the increasing demand for healthcare services worldwide. With its strategic approach, Healthcare LdrIncmUn stands out as a compelling choice for investors seeking to enhance their portfolios with the robust potential of the healthcare industry.

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron’s NCT07753148 study is formally titled “An Open-Label, Multi-Center Phase I Study to Investigate the Safety and

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly’s official study, “A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to


| Name | Weight % |
|---|---|
| REGNRegeneron Pharmaceuticals | 5.41% |
| AZNAstraZeneca plc | 5.14% |
| BMYBristol-Myers Squibb Company | 5.09% |
| ABTAbbott Laboratories | 5.01% |
| LLYEli Lilly And Company | 5.00% |
| MRKMerck & Company | 4.97% |
| VRTXVertex Pharmaceuticals Inc. | 4.94% |
| NVSNovartis AG | 4.92% |
| DHRDanaher Corporation | 4.88% |
| ABBVAbbvie | 4.87% |
| Total | 50.23% |